Bacterial Endotoxin Test (BET) is a vital safety requirement in the current good manufacturing practice (CGMP) regulations for finished pharmaceuticals and the medical device quality system regulations. A solid grasp of the concept of this critical release assay, its application and importance to the manufacture of cGMP product is paramount. This helps avoid costly errors, batch disposal, expensive failure investigations and delays in the release of products that some manufacturers have undergone. This webinar has been designed to provide the experienced technician with an extensive understanding of how an Limulus amebocyte lysate (LAL) testing program can be applied to quality control so that regulatory requirements enforced by the EU and the FDA are met.
Why You Should Attend:
The current requirements of USP <85> Bacterial Endotoxin Test (BET) and European Pharmacopoeia (Chapter 2.6.14) will be discussed in this 60 minute webinar. It will address the different LAL testing methodologies and how to choose the best test method applicable to the product type. This webinar will outline the significance, regulatory and testing requirements of products for compliance by applying the sequential steps in testing the product to rule out the presence of Endotoxins. Companies in the Pharmaceutical, Biotechnology and Medical Device Industries that manufacture cGMP products requiring bacterial Endotoxin release assay will greatly benefit from this program.
Areas Covered in the Session :
Who Should Attend: